Baxter BioPharma to provide fill/finish services for Moderna vaccine

By The Science Advisory Board staff writers

Baxter BioPharma has entered into an agreement with Moderna to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 vaccine in 2021.

Baxter is a contract manufacturing organization that specializes in parenteral (injected) pharmaceuticals, including vaccines. The manufacturing of Moderna's messenger RNA (mRNA)-based vaccine will take place at Baxter's fill/finish sterile manufacturing facilities located in Bloomington, IN. The site has capabilities and expertise in injectable delivery systems and clinical and commercial vaccine manufacturing.

Financial details of the agreement were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking